On February 27, 2026 Novartis AG (NYSE: NVS) reported that it has successfully completed its acquisition of Avidity Biosciences, Inc. ("Avidity"). With the completion of the acquisition, Avidity is now an indirect, wholly owned subsidiary of Novartis.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"Avidity’s breakthrough science combined with Novartis capabilities will help reimagine what’s possible for people with devastating genetic neuromuscular diseases," said Vas Narasimhan, CEO of Novartis. "Avidity’s muscle-directed AOC platform and late-stage programs advance our RNA therapeutics and have the potential to deliver first-in-disease therapies. With the close of the acquisition, we’re excited to welcome Avidity to Novartis and accelerate this next generation of medicines."

Novartis completed the acquisition of Avidity through the merger of its indirect wholly owned subsidiary, Ajax Acquisition Sub, Inc., with and into Avidity. As a result of the merger, holders of Avidity common stock became entitled to receive USD 72.00 per share in cash, valuing the company at approximately USD 12bn on a fully diluted basis and representing an enterprise value of approximately USD 11bn. Avidity’s shares of common stock have also ceased trading on the Nasdaq Stock Market LLC. The transaction was originally announced on Oct. 26, 2025.

(Press release, Novartis, FEB 27, 2026, View Source [SID1234663129])